S
troke is the leading cause of disability in the United States, and about 65% of survivors of stroke experience long-term upperextremity functional limitations. In more than half of patients with severe paresis after stroke, recovery of upper-extremity function is achieved solely by use of the less-affected limb. 1 Improving use of the moreaffected arm is important, however, because difficulty in using this arm in daily tasks has been associated with both reduced participation and quality of life. 2, 3 There now is evidence that intensive, task-specific practice, in which patients actively engage in repeated attempts to produce motor behaviors beyond their present capabilities, is effective for improving upperextremity function and use after stroke. 4 -9 Constraint-induced movement therapy (CIMT) in particular, which involves intense, functionally oriented task practice of the moreaffected upper limb along with restraint of the less-impaired limb for 90% of waking hours, was shown in the Extremity Constraint-Induced Therapy Evaluation (EXCITE) phase III randomized controlled trial to largely improve limb function and arm use compared with usual and customary care. 7,9 Several weeks of challenging rehabilitative training with the upper limb contralateral to the lesion reverses, at least partially, the loss of cortical representation due to stroke through recruitment of adjacent brain areas. 10 -12 Such reorganization may last several years after the initial injury 13 and has been linked to change in performance. 14 Long-term change in arm and hand use in the months following therapy, however, is variable among patients. In some patients, use continues to improve in the months following therapy. 9,15,16 Earlier, we proposed that the repeated attempts to use the affected arm in daily activities can promote motor learning that improves performance and function 15 ; this improvement in function, in theory, could further increase arm use. However, for other patients, improvements can be short-lasting. For a number of patients in the EXCITE trial, for instance (see Results section), and presumably for a larger number of patients who receive usual and customary care, a decrease in use of the affected arm appears in the year following therapy. If this decrease is large, rehabilitation is in vain. Accordingly, understanding the conditions that lead to sustained gains in arm use following an intense bolus of therapy is important. To achieve a unimanual task, such as drinking from a glass, a patient recovering from stroke can be conceptualized as a decision maker who chooses to use either the more-affected limb or less-affected limb (the decisions here need not be made consciously). The choice of limb use will presumably depend on many factors, including lesion characteristics, impairment and functional levels, motor training, previously rewarding or punishing experience after stroke, and motivation.
In a recent computational model, 17 we modeled bilateral reaching movements in patients recovering from stroke to explore the interactions between the adaptive decision process of limb use and limb performance. Here, "arm performance" is defined as the directional error of the movement toward the selected target and is the equivalent of "arm and hand function" in patients. Therapy is a simulation of CIMT: the simulated patient is forced to use the affected arm. When no therapy is given, the patient is free to choose 1 of the 2 arms to reach a target appearing on a circle centered on (overlapping) initial hand locations. Our neural model contains 2 independent motor cortices, each controlling the contralateral arm, with one being affected by stroke.* Before each movement, one motor cortex is selected by an adaptive decision-making system, tentatively located in cortico-striatal networks.
In our model, neural reorganization in the motor cortex was modeled with a neural learning rule that aims to achieve 2 goals concurrently. The first goal is to reorganize the neural code to increase arm performance via error-based learning (also called "supervised learning"). The second goal is to maximize neural resources for particular desired movement directions to minimize movement variability via Hebbian learning (a model of long-term potentiation, which also is called "unsupervised learning" because there is no teacher).
Furthermore, in the model, the decision to use one limb or the other is made by comparing the "action value" of each limb in the adaptive decision-making system. The values for each arm are updated based on reward prediction errors (this type of learning also is called "reinforcement learning"). If performancebased rewards are greater than expected, the arm will be chosen more often for this particular movement. If • The Bottom Line clinical summary
• The Bottom Line Podcast Specifically, we simulated 125 patients with locations of the lesion center randomly chosen within the affected motor cortex. The lesion sizes were empirically determined within a range of 16% to 43% of the affected motor cortex sizes, because such lesion sizes lead to effects that are neither too mild (to need therapy) nor too severe (to benefit from therapy). All patients received the same dose of 400 forced-use trials of therapy (corresponding to the 2 weeks of CIMT that was the standard dose in EXCITE). Then, for each simulated patient, we measured use of the affected arm just after therapy (corresponding to the 1-week posttest in the EXCITE trial) and in a delayed follow-up test, given after 3,000 free-choice trials following therapy (corresponding to the 1-year posttest in the EXCITE trial). All other simulation parameters are shown in Han et al. 17 We developed sigmoid models of spontaneous arm use as a function of the error both immediately after therapy and 3,000 trials after therapy. For this purpose, we fitted the equivalent linear models to the data:
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, USE is the average spontaneous arm use either just after therapy or 3,000 trials after therapy, and ERROR is the average of directional error (in degrees) just after therapy. USE and ERROR are computed from the average of 100 trials over the affected range. The parameter a is the sigmoid slope, the parameter b is a free parameter, and log is the natural logarithm. We report the P value obtained from these linear regression models with transformed Y values. We compared linear fits and sigmoid fits with root mean square error (RMSE) in spontaneous arm use.
Reanalysis of Clinical Data From the EXCITE Trial
The objective of this reanalysis of the data from the EXCITE clinical trial 7 was to test the prediction, derived from our simulations, of a performance threshold, on average, in patients poststroke.
We performed a retrospective analysis of data from the 169 patients enrolled in the EXCITE trial who did not withdraw from the trial. 7 Briefly, in the EXCITE trial, subjects were randomly assigned to either an im-
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mediate CIMT group or a delayed CIMT group. The immediate CIMT group received 2 weeks of therapy after inclusion in the study (Pre1); the delayed CIMT group received no immediate therapy but did receive 2 weeks of therapy after a 1-year delay (Pre2). Subjects were tested with the Wolf Motor Function Test (WMFT) and the Motor Activity Log (MAL) at Pre1, at 1 week after the immediate CIMT group received therapy (Post1), at Pre2, and at 1 week after the delayed CIMT group received therapy (Post2). All subjects were tested again at 24 months after inclusion in the study (MT24). 7, 19 In the current analysis, we compared arm use 1 week after therapy with arm use a year later, so time of therapy was not a factor in this analysis. We thus combined all data in the EXCITE trial at these points and studied arm function and use in the posttest just following therapy (Post1 for the immediate CIMT group and Post2 for the delayed CIMT group) and arm function and use in the delayed 1-year posttest (Pre2 for the immediate CIMT group and MT24 for the delayed CIMT group).
Briefly, the WMFT measures performance time (up to 120 seconds) needed for patients with stroke to perform 15 laboratory-based arm function tasks requiring use of the more-affected upper extremity. 20 -22 The WMFT also contains a shoulder strength (force-generating capacity) task and a grip strength task. Additionally, the quality of motor function during the timed tasks is assessed by independent raters using the 6-point Functional Activity Scale (FAS). The WMFT has good reliability and validity and has been shown not to suffer from a learning effect. 22 In our analyses, as in Wolf et al, 21 the natural logarithm of the WMFT time score was used to normalize the distribution. In this analysis with sigmoidal models, we included only patients with WMFT and MAL data available at both time points (although all subjects included in our analysis completed the trial, a number of data points were missing at either the 1-week posttest or the 1-year posttest). Furthermore, to obtain convergence of the sigmoidal fit, we removed 2 subjects with perfect MAL AOU scores (scores of 5 at 1 week after therapy; no participants had scores of 5 at 1 year following therapy). We thus analyzed data from 132 subjects. We also compared sigmoidal models and linear models after removal of outliers, defined as individuals with residuals (observedpredicted values) greater than 2 standard deviations of the residuals.
We compared the sigmoid models at 1 week posttherapy and at 1 year posttherapy by computing and com-
paring the confidence intervals (CIs) at 95% and 90% of the slope parameter of the sigmoid regression models. We predicted that for those subjects whose performance was above threshold after therapy, use would increase from 1 week posttherapy to 1 year posttherapy. Contrarily, we predicted that for those subjects whose performance was below threshold, use would decrease. Assuming that sigmoid models are a good fit to the use data at 1 week posttherapy and at 1 year posttherapy, this prediction can be tested by the change in slope of the sigmoids from 1 week posttherapy to 1 year posttherapy. The slope should be greater at 1 year posttherapy than at 1 week posttherapy. Finally, the performance threshold was obtained at the crossing of the sigmoids at 1 week posttherapy and at 1 year posttherapy. The prediction is that the 2 curves will cross because the slope is greater at 1 year posttherapy than at 1 week posttherapy. Above this crossing point, use will be greater at 1 year posttherapy than at 1 week posttherapy, on average. Below this crossing point, use will be smaller at 1 year posttherapy than at 1 week posttherapy, on average. Thus, this crossing represents an average threshold. We set the significance level at Pϭ.05.
Results

Computer Simulation
To test the hypothesis that spontaneous use will increase in the months following therapy if arm performance after therapy is above a threshold, we first investigated arm use at 0 trials and at 3,000 trials following therapy as a function of performance just after therapy. For simulated patients above threshold, spontaneous arm use should increase, on average, from 0 to 3,000 trials. For patients below threshold, the spontaneous arm use should decrease, on average, from 0 to 3,000 trials.
In the model, performance is measured as angular error between the target direction and the actual arm movement direction. Spontaneous arm use is measured as percentage of use of the affected arm to the targets in the range of movement directions most affected by the lesion (in the model, the lesions affect some ranges more than others; see Han et al 17 for details). Figure 1A shows that for most simulated patients with high performance after therapy, spontaneous arm use was high and saturated to maximum use (100% in the model). Conversely, for simulated patients with low performance, use saturated near zero. Because of these ceiling and floor effects, arm use after therapy was fit better by a sigmoidal function of performance (RMSEϭ17.08, PϽ.0001) than by a linear function of performance (RMSEϭ18.74, PϽ.0001). Figure 1B shows that arm use in the follow-up test at 3,000 trials after therapy also was fit better by a sigmoidal function (RMSEϭ18.98, PϽ.0001) than by a linear function (RMSEϭ19.36, PϽ.0001). Finally, the slope of the sigmoid model in the long-term follow-up test was steeper than that just after therapy (slope just after therapyϭ0.31; slope 1 year after therapyϭ0.52).
The intersection of the 2 curves gives an average (or "group") threshold in arm performance, corresponding to a reaching error of 22.8 degrees. Above this threshold, the arm use of most simulated patients (89.1%) improved spontaneously following therapy; below this threshold, the arm use of most simulated patients (87.1%) worsened following therapy.
These simulation results make 3 testable predictions. First, the relationship between use after therapy and function after therapy is sigmoidal, and this is true if spontaneous use is measured just after therapy or in a delayed follow-up test. Second, the sigmoid is steeper in the follow-up test than just after therapy. Third, the intersection of the sigmoid for use just after therapy with the sigmoid for use in the long-term followup test (Fig. 1C) gives an average threshold in performance above which use improves spontaneously following therapy and below which use worsens. We next tested these predictions with a reanalysis of clinical data from the EXCITE trial.
Clinical Data Analysis
The correlation analysis between the difference in average MAL AOU scores from just after therapy to 1 year posttherapy and the logarithm of the WMFT time score shows that function (WMFT score) was positively correlated with change in use (MAL AOU scale score) ( The strength of the relationships between MAL AOU scale scores and WMFT FAS scores at 1 week and 1 year after therapy increased after removal of outliers. Based on our criterion for outlier removal, 4 subjects were removed in the 1-week model, 5 subjects were removed in the 1-year model, and 3 subjects were outliers for both the 1-week and 1-year models; thus, nϭ128 for the 1-week model and nϭ127 for the 1-year model). Compared with the sigmoid models without outlier removal, these models with outlier removal (Figs. 2A and B) showed improved fit to the data (1 week after therapy: RMSEϭ0.76, PϽ.0001; 1 year after therapy: RMSEϭ0.79, PϽ.0001) and smaller CIs of the slopes both 1 week after and 1 year after therapy (1 week after therapy: mean slopeϭ1.44, SE of slopeϭ0.13, 95% CIϭ1.19 -1.68, 90% CIϭ1.23-1.64; 1 year after therapy: mean slopeϭ1.91, SEϭ0.14, 95% CIϭ 1.63-2.18, 90% CIϭ1.67-2.14). Finally, the sigmoid models with outlier removal fit the 1-week and 1-year data better than the linear models with outlier removal (1 week after therapy: nϭ130, RMSEϭ0.78,
Figure 1.
Simulated data of use of the affected arm (A) just after therapy and (B) 3,000 trials after therapy as a function of performance (reach directional error in the model) just after therapy for 125 simulated subjects with different lesion sizes and locations. (C) Comparison of the sigmoidal fit of use just after therapy and 3,000 trials after therapy. The intersection of the 2 curves gives the threshold in arm performance above which use increases and below which use decreases. The upward arrow indicates that 89.1% of the simulated subjects above threshold showed increased arm use after therapy. The downward arrow indicates that 87.1% of the simulated subjects below threshold showed decreased arm use after therapy. Note that we reversed the x axis, to compare with the data of Figure 2 .
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PϽ.0001; 1 year after therapy: nϭ129, RMSEϭ0.83, PϽ.0001).
Thus, the slope of the sigmoidal model 1 year after therapy was greater than the slope of the sigmoidal at 1 week after therapy, although there was a very small overlap of the 95% CIs (by 0.05) but no overlap of the 90% CIs. The results were qualitatively similar without outlier removal, but the 95% CIs for the sigmoid slopes overlapped somewhat (by 0.15); however, there was less overlap of the 90% CIs (by 0.06). The steeper slope of the sigmoid at 1 year posttherapy compared to 1 week posttherapy is well illustrated in Figure 2C , in which we plotted the 2 sigmoids (models without outliers).
The intersection of the 2 sigmoids with mean slopes gives the average threshold in function, given by WMFT FAS scoreϭ3.44. Among 22 subjects with function above this threshold, 15 (68.2%) showed an increase in use in the year following therapy (model without outliers). Conversely, among 104 subjects with function below this threshold, only 38 (36.5%) showed an increase in use in the year following therapy (Fig. 2C) . Thus, as predicted by the computational model, when function 1 week after therapy was above this average threshold, subjects on average showed improvements in use in the year following therapy, and when function 1 week after therapy was below this average threshold, subjects on average experienced a worsening of use in the year following therapy.
Figure 2.
Use of the more-affected arm, as recorded by the Motor Activity Log Amount of Use (MAL AOU) subscale: (A) 1 week after therapy and (B) 1 year after therapy as a function of arm and hand function (Functional Ability Scale [FAS]) 1 week after therapy for subjects of the EXCITE trial. (C) Comparison of the sigmoidal fit of use 1 week after therapy and 1 year after therapy. The intersection of the 2 curves gives the functional threshold (FAS scoreϭ3.44) above which uses increases and below which use decreases. The upward arrow indicates that 68.2% of subjects above threshold showed increased arm use after therapy. The downward arrow indicates that 63.5% of subjects below threshold showed decreased arm use after therapy.
Discussion
To better understand the interactions between arm function and use after therapy, we have presented new simulations with conditions that mimic those of the EXCITE trial. These simulations made 3 new predictions, all of which were confirmed in a reanalysis of arm use and function data from the EXCITE trial.
First, the relationship between use after therapy and performance is better fit by a sigmoidal model than a linear regression model, and this sigmoidal relationship is true whether use is measured 1 week after therapy or in a follow-up test. The differences, however, between the linear fits and sigmoidal fits are not very large (as shown by the relatively small differences in RMSE between linear and sigmoidal models at 1 week after therapy and at 1 year after therapy in the outlier removal conditions). Thus, this sigmoidal relationship needs to be verified with other clinical databases. A sigmoidal relationship can result for 2 possible, nonexclusive reasons. The first possible reason is simply that the MAL AOU scale does not adequately measure arm use when use is high or low. The second possible reason is an actual nonlinear relationship between function and use in patients, at least on average. A floor effect would suggest that when function is low, the arm is not used at all. A ceiling effect would suggest that when function is high but less than maximal, the arm is used as if the patient did not have a stroke.
Second, the sigmoid is steeper in the 1-year follow-up test than 1 week after therapy. This indicates that, for the average patient in EXCITE trial, if function is high 1 week after therapy, use improves. Conversely, and again on average, if function is low 1 week after therapy, use worsens.
Third, the intersection of the sigmoid for use 1 week after therapy with the sigmoid for use in the 1-year follow-up test gives an average (or group) threshold in function of WMFT FAS scoreϭ3.44. An FAS score of 3 is given if the affected arm performance does not require assistance from the other arm but is limited by synergistic movements, or is performed slowly or with effort. An FAS score of 4 is given if the affected arm performance is close to normal (ascertained by performance of the less-affected limb and with premorbid dominance considered) but slightly slower and may lack precision, fine coordination, or fluidity. If function is above the threshold 1 week after therapy, use of the moreaffected arm in the year following therapy improves, on average. On the contrary, if function is below this threshold, use is not sustained, on average. Thus, functional abilities just after therapy predict change in use in the long-term following therapy, and, on average, a functional threshold can be determined.
In the stepwise regression analysis of the EXCITE trial data, only a measure of arm and hand function (the WMFT FAS) and shoulder strength 1 week after therapy predicted change in use. Furthermore, shoulder strength was negatively correlated with a future change in use, although this correlation was only moderate (Ϫ.34). How can this result be interpreted? One possibility is that patients with greater shoulder strength may be better able to compensate with the proximal arm for the lowerfunctioning distal upper extremity. Because of these compensatory movements, use of the hand is not reinforced and decreases. Another, nonexclusive possibility is that increase in arm strength correlates with a shrinkage of neural areas encoding the distal representation and an increase in neural areas encoding the proximal representation; this would explain the negative correlation. In any case, because stepwise regression is an exploratory tool, these results and predictions warrant further investigation by studies that combine brain imaging or neural recording and behavioral data analysis. Furthermore, we note that we have defined shoulder strength as performance of the "weight to box" task of the WMFT. This task does not directly measure shoulder strength, and thus the correlation might be different if strength is tested with the actual shoulder strength test.
Limitations and Future Work
A practical clinical implication of the present work is the determination of a stopping criterion to determine the dose of therapy for each patient. The intersection of the sigmoid curves in our reanalysis of the EXCITE trial data gives a "group" threshold, above which most patients improve spontaneously.
A goal of our future research, therefore, is to provide the means to assess when an individual reaches his or her personal threshold so that therapy may be stopped without adverse effect. More research is needed, however, before we are able to provide robust threshold values for individual patients and before such a stopping rule can be implemented in the clinic, for the following reason. Notably, the predictive capability of our simple sigmoidal models is rather low: only 68.2% of subjects above the threshold showed improvement in use; conversely, 36.5% of subjects below the threshold showed improvement in use. Such low predictive values arise because our sigmoidal models are simple averaged models that do not consider individual lesion size, location, or any other patient characteristics, such as motivation, handedness, and so on, besides function 1 week after therapy.
To be able to determine functional thresholds for individual patients, we are currently extending this work in 2 aspects. First, we are developing individualized predictive Understanding the Functional Threshold for Paretic Hand and Arm Use After Therapy models that can be used for individualized determination of threshold and dose. We previously argued from a theoretical viewpoint, 17 and confirmed to some extent here with clinical data, that stroke recovery is a time-varying process (arm use changes in the year following therapy) that is nonlinear (arm use can increase or decrease in the year following therapy, depending on arm function after therapy). We currently are developing time-varying and nonlinear models of recovery that will use neurological data such as stroke lesion location and volume as regressors. Second, both the WMFT FAS and the MAL AOU scale are lengthy tests that are impractical to use in the clinic. To address this, we are developing a novel, easy-toadminister, reliable, and valid measure of arm use that is based on actual arm choices in a bilateral arm reaching task. 25 Based on predictions from these novel models and tools, we expect to determine the functional threshold with high confidence for individual patients and, as a result, to determine the patient-specific dose of therapy that will bring function above this threshold. Such an understanding of nonlinear relationships between limb function and use is important for the future development of cost-effective interventions and the prevention of "rehabilitation in vain." 
